Title: Testing if high dose radiation only to the sites of brain cancer compared to whole brain radiation that avoids the hippocampus is better at preventing loss of memory and thinking ability

Principal Investigator: Vinai Gondi, MD, NRG Oncology

Description: Investigators are conducting a phase 3 trial comparing the efficacy of stereotactic radiosurgery (SRS) with the standard of care memantine and hippocampal-avoidant whole-brain radiation therapy (HA-WBRT) for the treatment of patients with small-cell lung cancer (SCLC) that has spread to the brain.


Continue Reading

The participants will be randomly assigned to undergo SRS over 1 day (in some cases several days) or HA-WBRT once a day for 2 weeks. Patients treated with HA-WBRT will also receive oral memantine either once a day or twice a day for up to 24 weeks in the absence of disease progression or unacceptable toxicity.

The primary outcome measure of the study is time to neurocognitive failure. Key secondary outcome measures include preservation of neurocognitive function, overall survival, and incidence of adverse events.

To be eligible for this study, patients must have a pathologically (histologically or cytologically) proven diagnosis of small-cell lung cancer within 5 years of registration. For a complete list of eligibility criteria, please refer to the reference.

Status: Recruiting

This study is sponsored by NRG Oncology in collaboration with the National Cancer Institute.

Reference

Testing if high dose radiation only to the sites of brain cancer compared to whole brain radiation that avoids the hippocampus is better at preventing loss of memory and thinking ability. ClinicalTrials.gov Identifier: NCT04804644. Updated March 18, 2022. Accessed March 23, 2022. https://clinicaltrials.gov/ct2/show/NCT04804644